Aggressive statin therapy in multicenter and effectiveness for the reduction of intra-myocardial damage caused by non-ST elevation acute coronary syndrome: AMERICA study

Therapeutic Advances in Cardiovascular Disease

Volumn 3, Issue 5, 2009, Pages 357-365

  Hara, Hidehiko ^a   Nakamura, Masato ^a   Yokouchi, Itaru ^a   Kimura, Keiko ^a   Nemoto, Naohiko ^a   Ito, Shingo ^a   Ono, Tsuyoshi ^a   Itaya, Hideki ^a   Shiba, Masanori ^a   Wada, Masamichi ^a   Iijima, Raisuke ^a   Yamamoto, Masaya ^a   Yamamoto, Masato ^a   Hara, Hisao ^a   Takagi, Takuro ^b   Asahara, Toshiyuki ^b   Sugi, Kaoru ^b   Mitsuo, Kazuhisa ^c   Kobayashi, Nobuyuki ^d  

^a TOHO UNIVERSITY OHASHI MEDICAL CENTER   (Japan)

^b TOKYO ROSAI HOSPITAL   (Japan)

^c Nissan Tamagawa Hospital   (Japan)

^d Ota General Hospital   (Japan)

Author keywords

Coronary artery disease; Percutaneous coronary intervention (PCI); Statin

Indexed keywords

ACUTE CORONARY SYNDROME; AGED; AGED, 80 AND OVER; ANGIOPLASTY, BALLOON, CORONARY; BIOLOGICAL MARKERS; CHOLESTEROL, LDL; CREATINE KINASE; CREATINE KINASE, MB FORM; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; JAPAN; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIUM; NATRIURETIC PEPTIDE, BRAIN; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; TROPONIN T;

ATORVASTATIN; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CREATINE KINASE; CREATINE KINASE MB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; TROPONIN T;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG EFFICACY; FEMALE; HEART MUSCLE INJURY; HEART PROTECTION; HUMAN; JAPANESE; MALE; MULTICENTER STUDY; MYOCARDIAL DISEASE; PERCUTANEOUS CORONARY INTERVENTION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 70350036063     PISSN: 17539447     EISSN: None     Source Type: Journal    
DOI: 10.1177/1753944709338893     Document Type: Article

References (25)

1. Chan, A.W., Bhatt, D.L., Chew, D.P., Quinn, M.J., Moliterno, D.J., Topol, E.J. et al. (2002) Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 105: 691-696.
2. Chan, A.W., Bhatt, D.L., Chew, D.P., Reginelli, J., Schneider, J.P., Topol, E.J. et al. (2003) Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation 107: 1750-1756.
3. de Lemos, J.A., Blazing, M.A., Wiviott, S.D., Lewis, E.F., Fox, K.A., White, H.D. et al. (2004) Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. Jama 292: 1307-1316.
4. Dupuis, J., Tardif, J.C., Cernacek, P. and Theroux, P. ( 1999) Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 99: 3227-3233.
5. FRagmin and Fast Revascularisation during In Stability in Coronary artery disease Investigators. (1999) Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet 354: 708-715.
6. Hara, H., Nakamura, M., Yokouchi, I., Kimura, K., Nemoto, N., Ito, S. et al. (2007) Impact of Statin Therapy on Coronary Intervention for Non-ST Elevation Acute Coronary Syndrome With Decreased Low-Density Lipoprotein Cholesterol. J Cardiol 49: 113-123.
7. Herrmann, J., Lerman, A., Baumgart, D., Volbracht, L., Schulz, R., von Birgelen, C. et al. (2002) Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction. Circulation 106: 2180-2183.
8. Ioannidis, J.P., Karvouni, E. and Katritsis, D.G. ( 2003) Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. J Am Coll Cardiol 42: 1406-1411.
9. Jialal, I., Stein, D., Balis, D., Grundy, S.M., Adams-Huet, B. and Devaraj, S. ( 2001) Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 103: 1933-1935.
10. Kluft, C., de Maat, M.P., Gevers Leuven., Potter, J.A., van Loon, B.J. and Mohrschladt, M.F. (1999) Statins and C-reactive protein. Lancet 353: 1274.
11. Lacoste, L., Lam, J.Y., Hung, J., Letchacovski, G., Solymoss, C.B. and Waters, D. ( 1995) Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation 92: 3172-3177.
12. Liao, J.K. ( 2007) Safety and Efficacy of Statins in Asians. Am J Cardiol 99: 410-414.
13. Notarbartolo, A., Davi, G., Averna, M., Barbagallo, C.M., Ganci, A., Giammarresi, C. et al. (1995) Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol 15: 247-251.
14. Okazaki, S., Yokoyama, T., Miyauchi, K., Shimada, K., Kurata, T., Sato, H. et al. (2004) Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study. Circulation 110: 1061-1068.
15. Olsson, A.G., Schwartz, G.G., Szarek, M., Sasiela, W.J., Ezekowitz, M.D., Ganz, P. et al. (2005) High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. Eur Heart J 26: 890-896.
16. Omland, T., Persson, A., Ng, L., O'Brien, R., Karlsson, T., Herlitz, J. et al. (2002) N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 106: 2913-2918.
17. Pasceri, V., Patti, G., Nusca, A., Pristipino, C., Richichi, G. and Di Sciascio, G. ( 2004) Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 110: 674-678.
18. Plenge, J.K., Hernandez, T.L., Weil, K.M., Poirier, P., Grunwald, G.K., Marcovina, S.M. et al. (2002) Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 106: 1447-1452.
19. Ridker, P.M., Rifai, N., Pfeffer, M.A., Sacks, F.M., Moye, L.A., Goldman, S. et al. (1998) Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 98: 839-844.
20. Ridker, P.M., Rifai, N., Pfeffer, M.A., Sacks, F. and Braunwald, E. ( 1999) Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 100: 230-235.
21. Sacks, F.M., Pfeffer, M.A., Moye, L.A., Rouleau, J.L., Rutherford, J.D., Cole, T.G. et al. (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels, Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335: 1001-1009.
22. Scandinavian Simvastatin Survival Study Group. ( 1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389.
23. Schwartz, G.G., Olsson, A.G., Ezekowitz, M.D., Ganz, P., Oliver, M.F., Waters, D. et al. (2001) Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. Jama 285: 1711-1718.
24. Strandberg, T.E., Vanhanen, H. and Tikkanen, M.J. ( 1999) Effect of statins on C-reactive protein in patients with coronary artery disease. Lancet 353: 118-119.
25. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Longterm Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 339: 1349-1357.